Sagimet Advances Denifanstat Toward Phase 3 Acne Trial Enrollment

Sagimet Biosciences said its AURORA Phase 3 trial of denifanstat for moderate-to-severe acne remains on track to begin enrollment. No efficacy/safety results or timeline changes were provided, so the update is largely procedural but helps reduce near-term execution risk for the program.